Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination
Authors: Nicole L. Yates
Hua Xin Liao
Youyi Fong
Allan DeCamp
Nathan A. Vandergrift
William T. Williams
S. Munir Alam
Guido Ferrari
Zhi Yong Yang
Kelly E. Seaton
Phillip W. Berman
Michael D. Alpert
David T. Evans
Robert J. O'Connell
Donald Francis
Faruk Sinangil
Carter Lee
Sorachai Nitayaphan
Supachai Rerks-Ngarm
Jaranit Kaewkungwal
Punnee Pitisuttithum
James Tartaglia
Abraham Pinter
Susan Zolla-Pazner
Peter B. Gilbert
Gary J. Nabel
Nelson L. Michael
Jerome H. Kim
David C. Montefiori
Barton F. Haynes
Georgia D. Tomaras
Duke University
Fred Hutchinson Cancer Research Center
National Institute of Allergy and Infectious Diseases
University of California, Santa Cruz
Harvard Medical School
Armed Forces Research Institute of Medical Sciences, Thailand
Global Solutions for Infectious Diseases
Thailand Ministry of Public Health
Mahidol University
Sanofi Pasteur
Rutgers New Jersey Medical School
NYU School of Medicine
Walter Reed Army Institute of Research
University of Wisconsin Madison
Keywords: Medicine
Issue Date: 19-Mar-2014
Citation: Science Translational Medicine. Vol.6, No.228 (2014)
Abstract: HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.
ISSN: 19466242
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.